We found that combination therapy TAE226 plus SOR reduced HCC growth both in vitro and in vivo and affected the expression of tumour-promoting genes and multifunctional epigenetic changes via de-regulation of the nuclear interactome of FAK. The gene discussed is PTK2; the disease is hepatocellular carcinoma.